Erbliche Anfälligkeit für akute myeloische Leukämie
Die erbliche Anfälligkeit für akute myeloische Leukämie wird durch heterozygote GATA2-Mutationen vermittelt.
Gliederung
Hereditäre maligne Bluterkrankungen
|
|||||
|
Erbliche Anfälligkeit für akute myeloische Leukämie
| ||||
|
|
GATA2
| |||
|
Erbliche Anfälligkeit für myelodysplastisches Syndrom
| ||||
|
|
Juvenile myelomonozyäre Leukämie
| ||||
|
|
|
|
|
|
Referenzen:
| 1. |
Kode A et. al. (2014) Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts. [^] |
| 2. |
Smith ML et. al. (2004) Mutation of CEBPA in familial acute myeloid leukemia. [^] |
| 3. |
Matsunaga T et. al. (2003) Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. [^] |
| 4. |
Hahn CN et. al. (2011) Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. [^] |
| 5. |
et. al. (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. [^] |
| 6. |
Miller CA et. al. (2013) Genomic landscapes and clonality of de novo AML. [^] |
| 7. |
Brewin J et. al. (2013) Genomic landscapes and clonality of de novo AML. [^] |
| 8. |
Shlush LI et. al. (2014) Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. [^] |
| 9. |
Le Beau MM et. al. (1993) Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. [^] |
| 10. |
Horwitz M et. al. (1996) A family inheriting different subtypes of acute myelogenous leukemia. [^] |
| 11. |
Horwitz M et. al. (1996) Anticipation in familial leukemia. [^] |
| 12. |
Bollag G et. al. (1996) Biochemical characterization of a novel KRAS insertion mutation from a human leukemia. [^] |
| 13. |
Horwitz M et. al. (1997) Genetic heterogeneity in familial acute myelogenous leukemia: evidence for a second locus at chromosome 16q21-23.2. [^] |
| 14. |
Shields JA et. al. (2003) Bilateral orbital myeloid sarcoma as initial sign of acute myeloid leukemia: case report and review of the literature. [^] |
| 15. |
Falini B et. al. (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. [^] |
| 16. |
Grisendi S et. al. (2005) NPM mutations in acute myelogenous leukemia. [^] |
| 17. |
Barjesteh van Waalwijk van Doorn-Khosrovani S et. al. (2005) Somatic heterozygous mutations in ETV6 (TEL) and frequent absence of ETV6 protein in acute myeloid leukemia. [^] |
| 18. |
Lee JW et. al. (2006) The JAK2 V617F mutation in de novo acute myelogenous leukemias. [^] |
| 19. |
Jin L et. al. (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. [^] |
| 20. |
Mullican SE et. al. (2007) Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia. [^] |
| 21. |
Gale RE et. al. (2008) The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. [^] |
| 22. |
Garzon R et. al. (2008) Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. [^] |
| 23. |
Schlenk RF et. al. (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. [^] |
| 24. |
Calado RT et. al. (2009) Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. [^] |
| 25. |
Gelsi-Boyer V et. al. (2009) Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. [^] |
| 26. |
Delhommeau F et. al. (2009) Mutation in TET2 in myeloid cancers. [^] |
| 27. |
Carbuccia N et. al. (2009) Mutations of ASXL1 gene in myeloproliferative neoplasms. [^] |
| 28. |
Mardis ER et. al. (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. [^] |
| 29. |
Garzon R et. al. (2009) MicroRNA 29b functions in acute myeloid leukemia. [^] |
| 30. |
Marcucci G et. al. (2010) IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. [^] |
| 31. |
Harutyunyan A et. al. (2011) p53 lesions in leukemic transformation. [^] |
| 32. |
Boissel N et. al. (2011) Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. [^] |
| 33. |
Ding L et. al. (2012) Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. [^] |
| 34. |
Smith CC et. al. (2012) Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. [^] |
| 35. |
Venstrom JM et. al. (2012) HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. [^] |
| 36. |
Santos MA et. al. (2014) DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier. [^] |
| 37. |
Wong TN et. al. (2015) Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. [^] |
| 38. |
Illendula A et. al. (2015) Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice. [^] |
| 39. |
Fong CY et. al. (2015) BET inhibitor resistance emerges from leukaemia stem cells. [^] |
| 40. |
Rathert P et. al. (2015) Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. [^] |
| 41. |
Ivey A et. al. (2016) Assessment of Minimal Residual Disease in Standard-Risk AML. [^] |
